Literature DB >> 11176387

Basic fibroblast growth factor expression in Peyronie's disease.

J P Mulhall1, J Thom, T Lubrano, T V Shankey.   

Abstract

PURPOSE: Peyronie's disease is a fibromatosis resulting in scarring of the tunica albuginea. While the inciting event is believed to be trauma to the erect penis, little is understood about the cascade of cellular events that leads to the formation of the plaque. Dysregulated wound healing serves as a paradigm for the study of this condition. Previous work has demonstrated a role for fibrogenic cytokines in wound healing, fibromatoses, including Peyronie's disease. We analyze the expression of the fibrogenic cytokine, basic fibroblast growth factor (FGF), by fibroblasts derived from Peyronie's disease tissue.
MATERIALS AND METHODS: Patients with Peyronie's disease undergoing either penile prosthesis insertion or Nesbit penile plication surgery had biopsy specimens removed from the plaque and from normal tunical tissue remote from the plaque. Cell cultures were derived from these specimens. Cultured cells were characterized using immunofluorescence staining and immunosorbent digital imaging. The cell culture supernatants were analyzed using an enzyme-linked immunosorbent assay for the production of basic FGF. Foreskin tissue from men without Peyronie's disease was used as control cells.
RESULTS: Five independent cell lines were established from plaque tissue and 4 independent cell lines were established from normal tunica from the same subjects. Intracellular antigen expression was consistent with the cells being myofibroblasts. Production of basic FGF by the plaque derived myofibroblasts was significantly greater compared to production by normal tunical myofibroblasts and foreskin fibroblasts.
CONCLUSIONS: These data demonstrate the successful establishment of cell lines from plaque tissue and normal tunica from men with Peyronie's disease. The findings indicate a potential role for basic FGF over expression in the tunical fibrosis that occurs in this condition. This information may allow a better understanding of the basic mechanisms involved in the development of this disease. Furthermore, it may permit the elaboration of therapeutic strategies to prevent or reduce tunical scarring and plaque formation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176387     DOI: 10.1097/00005392-200102000-00016

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

2.  Screening of candidate genes in fibroblasts derived from patients with Dupuytren's contracture using bioinformatics analysis.

Authors:  Haoyu Liu; Weitian Yin; Biao Liu; Yan Liu; Baofeng Guo; Zhuang Wei
Journal:  Rheumatol Int       Date:  2015-05-12       Impact factor: 2.631

Review 3.  Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction.

Authors:  Jeffrey Campbell; Raidh Alzubaidi
Journal:  Transl Androl Urol       Date:  2017-02

Review 4.  The pathophysiology of Peyronie's disease.

Authors:  Ahmed I El-Sakka; Emre Salabas; Murat Dinçer; Ates Kadioglu
Journal:  Arab J Urol       Date:  2013-08-07

5.  Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Authors:  Gianni Paulis; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Giuseppe Dachille; Andrea Fabiani; Romano Gennaro
Journal:  Res Rep Urol       Date:  2015-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.